Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Phil King discusses the Opthea fiasco, his current outlook and whether we’ve seen the bottom in equity markets.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary endpoint.

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Sozinibercept combination therapy was well tolerated. Following the receipt of these results, Opthea has undertaken a thorough review of the data to ensure both its accuracy and integrity.

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea Limited - Depositary Receipt ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea (OTCPK:CKDXF) from Buy to ...

Following the negative results of the COAST Phase 3 trial announced on 24 March 2025, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other ...

Opthea, which is 30 per cent owned by Regal Funds Management, has been running two phase three clinical trials into its flagship compound sozinibercept, for the treatment of the eye disease ...

Opthea’s flagship clinical trial has failed, arguably triggering payments to funders which could push the Regal-backed firm into insolvency. Opthea, which is 30 per cent owned by Regal Funds ...